Get the Stockscreener App
39.15
2.37%
-0.95
Pre-market:
39.20
0.05
+0.13%
Qiagen Nv stock is traded at $39.15, with a volume of 2.22M.
It is down -2.37% in the last 24 hours and up +6.73% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$40.10
Open:
$39.425
24h Volume:
2.22M
Relative Volume:
1.02
Market Cap:
$8.07B
Revenue:
$2.10B
Net Income/Loss:
$402.17M
P/E Ratio:
20.23
EPS:
1.9357
Net Cash Flow:
$403.87M
1W Performance:
-1.61%
1M Performance:
+6.73%
6M Performance:
-16.72%
1Y Performance:
-19.01%
1-Day Range:
$38.73
$39.58
1-Week Range:
$38.63
$40.18
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, NTRA, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
39.15 | 8.06B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
517.60 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.62 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.98 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
283.80 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
378.89 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen N.V. highlights digital PCR expansion. Stock trades near recent highs on Nasdaq - AD HOC NEWS
Qiagen earnings calendar and diagnostics pipeline, shares watched by international investors - AD HOC NEWS
Qiagen earnings calendar stands out this week, shares steady on Xetra - AD HOC NEWS
Qiagen steady ahead of earnings, shares watched by analysts - AD HOC NEWS
QIAGEN NV Actuals & Estimates (TURQUOISE:QIAD) - TradingView
The QIAamp DNA Mini Kit from Qiagen N.V.quiet lab workhorse for clean samples - AD HOC NEWS
Qiagen N.V.(NYSE: QGEN) added to Russell 1000 Dynamic Index - marketscreener.com
Qiagen consistent with diagnostics strategy, shares follow sector trend - AD HOC NEWS
QIAGEN NV Actuals & Estimates (AQUISUK:QIAD) - TradingView
Qiagen expands QIAcuity gene expression tools, shares remain muted on NYSE - AD HOC NEWS
QIAGEN NV Actuals & Estimates (VIE:QGE4) - TradingView
Qiagen N.V. refines diagnostics portfolio, shares backed by long-term strategy - AD HOC NEWS
Qiagen steadies after recent pullback, shares tracked on NYSE and Xetra - Ad-hoc-news.de
Enterprise value to EBIT forward of Qiagen N.V. – NYSE:QGEN - TradingView
Qiagen updates its diagnostics focus, shares anchored in health-care demand - AD HOC NEWS
QGEN Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Qiagen N.V. – NYSE:QGEN - TradingView
Qiagen earnings calendar and diagnostics outlook, shares in focus for Nasdaq investors - AD HOC NEWS
Qiagen extends its recent high, shares near 52-week peak on NYSE and Xetra - AD HOC NEWS
Bloodstream Infection Testing Market Size to Reach USD 1,404.68 Million by 2035 | SNS Insider - GlobeNewswire Inc.
QIAGEN NV Actuals & Estimates (BIVA:QIA/N) - TradingView
Qiagen N.V. updates earnings calendar, shares tracked against diagnostics peers - AD HOC NEWS
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen adjusts portfolio in Europe, shares track diagnostics peers - Ad-hoc-news.de
QIAGEN NV Actuals & Estimates (NYSE:QGEN) - TradingView
Qiagen publishes new sustainability report, shares backed by fresh analyst support - Ad-hoc-news.de
Enterprise value to EBITDA forward of Qiagen N.V. – NYSE:QGEN - TradingView
Kepler Cheuvreux Initiates Qiagen Coverage at Hold - marketscreener.com
Is Qiagen's (QGEN) Digital PCR Expansion Quietly Redefining Its Competitive Moat in Biopharma Tools? - simplywall.st
Qiagen N : Sustainability Report (ca ab 1305 voluntary carbon market disclosure 2026) - marketscreener.com
Qiagen N : Sustainability Report (ca ab 1305 voluntary carbon market disclosure) - marketscreener.com
Qiagen NV Annual Shareholders Meeting Transcript - GuruFocus
Qiagen (QGEN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Morgan Stanley Upgrades Qiagen to Overweight, Raises PT - marketscreener.com
QGEN Upgraded by Morgan Stanley -- Price Target Raised to $42.00 - GuruFocus
Barclays Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $38 - Moomoo
Qiagen annual meeting in Venlo, shares under DAX investor scrutiny - Ad-hoc-news.de
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen updates draw analyst attention, shares react on NYSE and Xetra - Ad-hoc-news.de
Qiagen Raised to Overweight From Equal-Weight by Morgan Stanley - Moomoo
Qiagen gets a DZ Bank lift, analyst consensus shapes the shares - Ad-hoc-news.de
QIAGEN NV : Gets a Buy rating from DZ Bank - marketscreener.com
Qiagen NV (QGEN) Institutional Confidence - TradingKey
Morgan Stanley Upgrades Qiagen NV(QGEN.US) to Buy Rating, Raises Target Price to $42 - Moomoo
Qiagen strategy and digital PCR expansion, shares tracked on Xetra and NYSE - AD HOC NEWS
Qiagen NV: QIAGEN N.V.Share Consolidation/Cash Distribution Option Symbol: QGEN New Symbol: QGEN1 - Moomoo
Qiagen Stockweekly outlook with earnings ahead - AD HOC NEWS
Qiagen NV (QGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Goldman Sachs Reports 2.87% Stake in Qiagen via Equity and Derivatives - The Globe and Mail
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):